Gilead will pay $175 million upfront for Cell Design Labs and will dish out additional payments of up to $322 million if certain milestones are hit.
The acquisition equips Gilead with additional resources to focus on the development of CAR-T cell therapies, which are personalized medications that genetically alter patients’ immune cells to attack cancer.
Cell Design is currently working on a custom cell engineering technology, including early state treatments for prostate cancer, which Gilead hopes to capitalize on.
More articles on supply chain:
Prescription drug spending slows in 2016: 5 things to know
Worsening IV fluid shortage forces New York hospital to transfer patient
FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
